Vyriad
Vyriad develops targeted viral genetic medicines and oncolytic therapies. Its BCMA-directed in vivo CAR-T candidate VV169 uses a retargeted lentiviral vector to engineer T cells inside the body. On September 10, 2026, the company announced that its Phase 1 study in relapsed/refractory multiple myeloma was open for enrollment at Mayo Clinic following FDA IND clearance. Patient dosing and clinical benefit were not established in that announcement.
Corporate information
- Company entity
- Vyriad
- Headquarters / principal office
- Rochester, Minnesota, United States ↗
- Founded
- 2015 ↗
- Ownership / capital status
- PrivateSeries B: US$25 million final tranche; US$85 million round total ↗
- Official corporate reference
- https://vyriad.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
- Latest financing / award identified
- 2025-12-23 · Series B — final tranche · US$25 million final tranche (US$85 million total Series B) ↗
Final tranche only; US$85 million is this round total, not all-time cumulative funding.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Vyriad develops targeted viral genetic medicines and oncolytic therapies. Its BCMA-directed in vivo CAR-T candidate VV169 uses a retargeted lentiviral vector to engineer T cells inside the body. On September 10, 2026, the company announced that its Phase 1 study in relapsed/refractory multiple myeloma was open for enrollment at Mayo Clinic following FDA IND clearance. Patient dosing and clinical benefit were not established in that announcement.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Vyriad — primary program / ownership disclosure
- Vyriad final Series B tranche, 23 December 2025
- Vyriad Begins Phase 1 Clinical Trial for Lead In Vivo CAR T Cell Therapy VV169 Following FDA Acceptance of IND Application
- Founding / incorporation disclosure — scope stated in field